Explore the words cloud of the SYNTRAIN project. It provides you a very rough idea of what is the project "SYNTRAIN" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||3˙990˙269 €|
|EC max contribution||3˙990˙269 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2016-09-01 to 2020-08-31|
Take a look of project's partnership.
|1||KOBENHAVNS UNIVERSITET||DK (KOBENHAVN)||coordinator||580˙163.00|
|2||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||546˙575.00|
|3||KANCERA AB||SE (SOLNA)||participant||527˙318.00|
|4||KAROLINSKA INSTITUTET||SE (STOCKHOLM)||participant||527˙318.00|
|5||STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS||NL (AMSTERDAM)||participant||510˙748.00|
|6||KRAEFTENS BEKAEMPELSE||DK (KOEBENHAVN)||participant||290˙081.00|
|7||UNIVERSITE DE GENEVE||CH (GENEVE)||participant||265˙226.00|
|8||IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE||IT (MILANO)||participant||258˙061.00|
|9||ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON||EL (ATHINA)||participant||242˙386.00|
|10||PANEPISTIMIO PATRON||EL (RIO PATRAS)||participant||242˙386.00|
|11||MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN||DE (DARMSTADT)||partner||0.00|
|12||MISVIK BIOLOGY OY||FI (TURKU)||partner||0.00|
|13||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||partner||0.00|
Breast and ovarian cancer constitute serious health challenges in the EU. To identify new improved cancer therapeutic approaches, we will pursue a multi-facetted synthetic lethal approach, which takes advantage of the inherent genetic instability of cancer cells. Most mutations acquired by cancer cells do not cause lethality, but the very same mutations may cause cell death when a second gene in a redundant pathway is inactivated. Thus, targeting a gene that is synthetic lethal together with a cancer-specific mutation will kill only cancer cells while sparing normal cells. Synthetic lethal approaches have been clinically pioneered by members of our consortium, by combining cancer-promoting mutations (e.g. in BRCA2) with inactivating combinations of DNA repair genes. We will use this approach as the scientific frame for our ETN (SYNTRAIN) consisting of 9 academic and 1 SME beneficiary as well as 3 partners. We aim to identify synthetic lethal interactions and exploit them to innovate future breast and ovarian cancer treatments through compound screening and development. SYNTRAIN consists of World leading researchers with complementary knowledge in genome maintenance and stress response pathways, and a critical mass of expertise for providing an excellent training in screening methodologies, mechanistic investigations, and drug discovery. We will offer a structured training program that exceeds the capacities of each individual member. We will educate a future generation of cancer researchers with a high innovative capacity and skills that enhances their career prospects in both academia and industry. Our aims are to train young researchers: i) in techniques preparing for a career in cancer research, ii) in complementary skills relevant for work in academia and the pharma industry and iii) to become creative and entrepreneurial, capable of bridging the gap between basic and applied research.
|SYNTRAIN website||Websites, patent fillings, videos etc.||2019-07-18 19:16:30|
Take a look to the deliverables list in detail: detailed list of SYNTRAIN deliverables.
|year||authors and title||journal||last update|
Timo ReislÃ¤nder, Emilia Puig Lombardi, Florian J. Groelly, Ana Miar, Manuela Porru, Serena Di Vito, Benjamin Wright, Helen Lockstone, Annamaria Biroccio, Adrian Harris, Arturo LondoÃ±o-Vallejo, Madalena Tarsounas
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-11048-5
|Nature Communications 10/1||2020-03-05|
Panagiotis Galanos, George Pappas, Alexander Polyzos, Athanassios Kotsinas, Ioanna Svolaki, Nickolaos N. Giakoumakis, Christina Glytsou, Ioannis S. Pateras, Umakanta Swain, Vassilis L. Souliotis, Alexandros G. Georgakilas, Nicholas Geacintov, Luca Scorrano, Claudia Lukas, Jiri Lukas, Zvi Livneh, Zoi Lygerou, Dipanjan Chowdhury, Claus Storgaard SÃ¸rensen, Jiri Bartek, Vassilis G. Gorgoulis
Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability
published pages: , ISSN: 1474-760X, DOI: 10.1186/s13059-018-1401-9
|Genome Biology 19/1||2019-07-18|
Eirini-Stavroula Komseli, Ioannis S. Pateras, ThorbjÃ¸rn Krejsgaard, Konrad Stawiski, Sophia V. Rizou, Alexander Polyzos, Fani-Marlen Roumelioti, Maria Chiourea, Ioanna Mourkioti, Eleni Paparouna, Christos P. Zampetidis, Sentiljana Gumeni, Ioannis P. Trougakos, Dafni-Eleftheria Pefani, Eric Oâ€™Neill, Sarantis Gagos, Aristides G. Eliopoulos, Wojciech Fendler, Dipanjan Chowdhury, Jiri Bartek, Vassilis G. Gorgoulis
A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence
published pages: 37-58, ISSN: 1471-2164, DOI: 10.1186/s12864-017-4375-1
|BMC Genomics 19/1||2019-07-18|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYNTRAIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SYNTRAIN" are provided by the European Opendata Portal: CORDIS opendata.